Using Artificial Intelligence-based ChatBot to Improve Women's Participation to Cervical Cancer Screening Programme

Официальное название

Artificial Intelligence-assisted Decision-making to Improve Women's Participation to Cervical Cancer Screening in Occitanie Region-France

Обзор

This project looks to improve the return rate of HPV self-sampling (HPVss) as well as the management of women HPVss positive.

Подробное описание

France has already implemented a cervical screening programme based on HPV test for the whole female population aged 30-65 years. Non-participant women can perform HPV test at their home. However, less than 20% of French women performed vaginal self-sampling when a kit was sent to their home. Women with lower income and educational levels participate less to cervical screening. A variety of personal, practitioner, test-related and logistical barriers negatively impact the screening participation of French women. Key barriers to participation could be addressed by overcoming disparities in HPV-related knowledge and perceptions about cervical cancer screening. This study aims to evaluate the impact of sending HPV self-sampling kit at women's home, associated with providing, through multiple mobile channels, a multi-language decision aid designed for women with lower education accessible via artificial intelligence-based ChatBot. This decision aid will help women review high quality evidence on cervical cancer disease and screening modalities.

Вмешательства

• Поведенческое Decision aid tailored to women with lower educational attainment,accessible via artificial intelligence-based Chatbot platforms
  Non-compliant women those that have not been screened for more than 4 years and living in the disadvantaged areas will be sent screening reminder letters to perform HPV self-sampling (HPVss) test, with access to decision aid tailored to women with lower education attainment and available via Chatbot platforms. ChatBot will deliver information in a responsive, conversational way via text and spoken language in multiple languages through multiple mobile channels.

Первичные конечные точки

• HPV self-sampling "return" rate [Срок оценки: 1 year after postal mail]
• Proportion of HPVss-positive women "well managed" [Срок оценки: 1 year after postal mail]
• Cost and cost-efficacy [Срок оценки: Month 36 - Month 48]

Критерии участия

Inclusion criteria: eligible women will be:

• aged 30-65
• did not perform a pap smear in the last 4 years
• are living in deprived clusters in the Occitanie region.
• did not answer to a first "invitation" letter to perform a clinician-collected HPV testing

Exclusion criteria: ineligible women will be those:

• outside the target age group
• had a Pap smear in the past 3 years
• had hysterectomy including cervix
• are pregnant
• already scheduled a screening appointment or had just attended a HPV screening
• had a cervical abnormality that was under exploration and/or treatment.
• participated to the study pilot

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Скрининг

Центры проведения

Франция · 1 центр

• Centre Régional de Coordination des Dépistages des Cancers-Centre d'Occitanie — Carcassone

Публикации

• Selmouni F, Guy M, Muwonge R, Nassiri A, Lucas E, Basu P, Sauvaget C. Effectiveness of Artificial Intelligence-Assisted Decision-making to Improve Vulnerable Women's Participation in Cervical Cancer Screening in France: Protocol for a Cluster Randomized Controlled Trial (AppDate-You). JMIR Res Protoc. 2022 Aug 2;11(8):e39288. doi: 10.2196/39288. PMID 35771872

Идентификаторы

NCT: NCT05286034 · IEC 21-16

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗